SAMIYAH ALKHALDI

Ms. SAMIYAH ALKHALDI

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
NMNahed Mahrous
Nahed Mahrous
MFMohannad M. Fallatah
Mohannad M. Fallatah
RFRawan Fitaihi
Rawan Fitaihi
HAHala Aldahshan
Hala Aldahshan
AAAreej Alhhazmi
Areej Alhhazmi
Yahya F. JamousYahya F. Jamous
Yahya F. Jamous
Antimicrobial resistance (AMR) is an ever-growing threat to global healthcare. It is largely driven by delayed or inadequate pathogen identification and antimicrobial susceptibility testing in routine clinical workflows. By the time the clinician receives results to guide treatment from traditional culture-based diagnostics, several days may have elapsed, leading to the use and potential over-prescription of broad-spectrum antibiotics and the development of resistant pathogens. A rapid and clinically actionable diagnostic approach at the clinical point of care (POC) may help address this gap. This review examines current and emerging POC diagnostic technologies for AMR and outlines the fundamental principles and mechanistic classifications of POC diagnostic technologies. These include phenotypic, genotypic, immunological, and biosensor-based approaches. A critical overview of key technological platforms, including rapid phenotypic antimicrobial susceptibility testing (AST), microfluidics and isothermal nucleic acid amplification (e.g., LAMP and RPA), CRISPR-based diagnostics, nanomaterial-enhanced biosensors, and mobile-integrated systems is provided. The impact of POC diagnostics on antimicrobial stewardship, time to appropriate therapy, and patient outcomes in primary care settings, hospitals, intensive care units, and resource-limited settings is presented and discussed. In addition to clinical implementation challenges, this review considers the issues of analytical performance, workflow, regulatory pathways, cost, and implementation readiness. In addition, it outlines key trends regarding digital integration, surveillance, workforce training, and policy frameworks. Overall, the review outlines the role of POC diagnostics in enhancing antimicrobial response surveillance and the global fight against AMR. Among emerging platforms, rapid phenotypic AST, microfluidic and isothermal-based assays, CRISPR-based diagnostics, and integrated biosensor systems show the greatest potential for near-term clinical impact; however, widespread implementation remains constrained by challenges related to clinical validation, cost, workflow integration, and alignment with antimicrobial stewardship frameworks.

23 July 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MFMohannad M. Fallatah
Mohannad M. Fallatah
SASAMIYAH ALKHALDI
SAMIYAH ALKHALDI
DADimah K Alrabiah
Dimah K Alrabiah
IAIbrahim Alradwan
Ibrahim Alradwan
MAMohammad Nasser Alkhrayef
Mohammad Nasser Alkhrayef
AAAhmad Mohammad Aldossary
Ahmad Mohammad Aldossary
RNA vaccines have emerged as an attractive platform for treating infectious diseases, cancer immunotherapy, and personalized medicine; however, their clinical success depends on multiple factors, including efficient, stable, and scalable delivery systems. Because RNA molecules are highly sensitive to factors such as enzymatic degradation, oxidation, poor cellular uptake, and limited endosomal escape, nanocarrier platforms play essential roles in protecting RNA cargo and enabling effective intracellular delivery. The biological performance of RNA nanocarriers depends on efficient cellular uptake, endosomal escape, intracellular RNA delivery, biodistribution, and immune modulation. Comparative assessment emphasizes that lipid nanoparticles remain the most clinically mature approach, while nanostructured lipid carriers, polymeric systems, and exosome-based nanocarriers provide multiple benefits for stability, targeted delivery, biocompatibility, and/or controlled release. Translational challenges involving GMP manufacturing, batch reproducibility, regulatory expectations, and scale-up are considered critical for effective nano-based RNA vaccine delivery and are elaborated in this review. Emerging advances such as pKa-tuned ionizable lipids, ligand-targeted systems, stimuli-responsive nanocarriers, circular and self-amplifying RNA platforms, artificial intelligence-guided formulation design, and needle-free delivery technologies may further expand the safety, accessibility, and therapeutic potential of RNA vaccines. In this review, we highlight next-generation nanocarrier systems for RNA vaccines, with an emphasis on novel nanocarrier RNA vaccine delivery systems. Additionally, we evaluate stability engineering approaches that currently limit global vaccine distribution and the future of the nanocarrier platforms for RNA vaccines.

13 November 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
FAFaisal Alagrafi
Faisal Alagrafi
SASAMIYAH ALKHALDI
SAMIYAH ALKHALDI
MAMohammad Nasser Alkhrayef
Mohammad Nasser Alkhrayef
IAIbtihal Alduhaymi
Ibtihal Alduhaymi
MAMusaad Altammami
Musaad Altammami
Yahya F. JamousYahya F. Jamous
Yahya F. Jamous
Secretory immunoglobulin A (SIgA) represents the most abundant antibody isotype at mucosal surfaces and plays a central role in maintaining intestinal immune homeostasis. In addition to its classical function in immune exclusion of pathogens, SIgA actively shapes the composition, spatial organization, and functional behavior of the gut microbiota, thereby contributing to a dynamic and reciprocal host–microbe relationship. Increasing evidence highlights that crosstalk between SIgA and the gut microbiota is not merely protective but also regulatory, influencing immune tolerance, barrier integrity, and inflammatory balance within the intestinal mucosa. This review provides a comprehensive overview of the molecular and immunological mechanisms underlying SIgA–microbiota interactions in mucosal immunity. We discuss the processes governing SIgA induction, class switching, and antigen specificity, as well as the mechanisms by which SIgA selectively coats commensal and pathogenic microorganisms. Emphasis is placed on how SIgA-mediated immune modulation shapes microbial ecology, limits immune overactivation, and maintains long-term mucosal homeostasis. Moreover, the review describes the role of dysregulation in SIgA–microbiota interactions in immune-mediated and inflammatory diseases, as well as the emerging translational perspectives. This includes the potential of SIgA-targeted strategies to modulate the gut microbiota for therapeutic benefit. By integrating mechanistic insights with clinical relevance, this review highlights SIgA–microbiota interactions at the intersection of mucosal immunology and emerging immunotherapeutic opportunities.

27 June 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HAHadi Alasmari
Hadi Alasmari
SAShouq Fahad Alghannam
Shouq Fahad Alghannam
HAHassan Almoammar
Hassan Almoammar
DADimah K Alrabiah
Dimah K Alrabiah
SASeham Alharthy
Seham Alharthy
AAAhmad Mohammad Aldossary
Ahmad Mohammad Aldossary
Ribonucleic acid-based vaccines have emerged as one of the most significant advances in modern vaccine development, demonstrating remarkable clinical success and enabling rapid responses to emerging infectious diseases. Despite their therapeutic potential, the development of these vaccines remains challenging because of the inherent instability of ribonucleic acid molecules, their susceptibility to degradation, and the complexity of formulation design. Ensuring product quality, stability, and biological performance therefore requires comprehensive analytical characterization throughout development, manufacturing, storage, and quality control. This review provides a comprehensive overview of current analytical strategies used to evaluate ribonucleic acid-based vaccine formulations. Key analytical approaches for assessing molecular integrity, purity, encapsulation efficiency, particle morphology, size distribution, surface characteristics, structural attributes, and biological potency are discussed. The review also examines the influence of formulation composition, lipid nanoparticle design, manufacturing processes, and storage conditions on vaccine stability and performance. In addition, major degradation pathways, critical quality attributes, and analytical challenges associated with quality assessment are highlighted. Furthermore, current regulatory considerations and limitations of existing analytical methodologies are discussed, particularly the challenges associated with establishing robust relationships between physicochemical properties and biological efficacy. The review emphasizes the importance of integrated multi-method analytical approaches for comprehensive characterization and quality assurance. Continued advances in analytical technologies and standardization efforts will be essential for supporting the development of safe, effective, and stable ribonucleic acid-based vaccines and for facilitating their broader pharmaceutical applications.